Cargando…
Evaluation of cardiovascular risk in a lung cancer screening cohort: what value does it bring?
There is a significant opportunity to improve cardiovascular disease (CVD) outcomes in lung cancer screening cohorts with a low-cost, noninvasive assessment of CVD risk, alongside existing assessments https://bit.ly/3a6Ha41
Autores principales: | Guariglia, Andrea, Davies, Iona J., Kanellakis, Nikolaos I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792827/ https://www.ncbi.nlm.nih.gov/pubmed/33447290 http://dx.doi.org/10.1183/20734735.0204-2020 |
Ejemplares similares
-
Management of incidental nodules in lung cancer screening: ready for prime-time?
por: Kanellakis, Nikolaos I., et al.
Publicado: (2019) -
Targeted therapies for lung cancer: how did the game begin?
por: Kanellakis, Nikolaos I., et al.
Publicado: (2016) -
Interstitial lung abnormalities a risk factor for rheumatoid arthritis interstitial lung disease progression: what's new
por: Leone, Paolo Maria, et al.
Publicado: (2020) -
Lung cancer incidence and mortality with extended follow-up in the National LungScreening Trial
por: Frille, Armin, et al.
Publicado: (2020) -
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
por: Cazzaniga, Marina Elena, et al.
Publicado: (2019)